With the acquisition of emovis, the Berlin-based dedicated study site and award-winning pan-European Homecare Visits and DCT solution provider, and by boosting DCT readiness across the entire network, FutureMeds has become the first DCT Site Network in Europe. Radoslaw Janiak, CEO at FutureMeds, said, “We’re excited to drive meaningful momentum and results for our clients and patients. Speeding up the DCT adaptation process across the clinical trial industry in Europe can boost pharmaceutical R&D productivity, support and influence commercialisation strategies, and...